4th Quarter - Report

STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 11, 2018 $50,000 Replaced
4th Quarter - Amendment Jan 12, 2018 $50,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization orphan drug provisions of HR 1, Tax Cuts and Jobs Act

LobbyistCovered position, as disclosed
JAMES DERDERIAN —
SARAH HAMLETT New Legislative Director, Rep. Thelma Drake; Legislative Assistant, Rep. Schrock
VALERIE HENRY —
JOSEPH RACHINSKY New —
EMILY SHETTY —
ERIN STRAWN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.